Clinical Trial Update: Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase 3 trial comparing RPR109881 versus capecitabine in patients with metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• RPR109881

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer, Metastases | Phase 3 | Status: COMPLETED